Pharma investing: A good bet?

The folks over at the Motley Fool are wondering if big pharma remains a safe haven in challenging investment times or whether its time for investors to jump ship. Writer Brian Orelli notes that some of big pharma's strongest players were down, but not as down as the Dow and the S&P 500 when the market tanked on Monday. Article

Suggested Articles

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?

Krystal Biotech has started on a new manufacturing facility for eventual commercial supply of gene therapies in its pipeline.

Chinese authorities have recommended trying AbbVie's HIV combo therapy Kaletra to treat the new coronavirus ravaging the country—and spreading fast.